These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35938771)

  • 1. Mast cell activation syndrome and the link with long COVID.
    Arun S; Storan A; Myers B
    Br J Hosp Med (Lond); 2022 Jul; 83(7):1-10. PubMed ID: 35938771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine Mast Cell Mediators in the Evaluation and Diagnosis of Mast Cell Activation Syndrome.
    Voelker D; Pongdee T
    Curr Allergy Asthma Rep; 2024 Feb; 24(2):33-38. PubMed ID: 38236528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast cell activation symptoms are prevalent in Long-COVID.
    Weinstock LB; Brook JB; Walters AS; Goris A; Afrin LB; Molderings GJ
    Int J Infect Dis; 2021 Nov; 112():217-226. PubMed ID: 34563706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adult-onset mast cell activation syndrome following scombroid poisoning: a case report and review of the literature.
    Brock I; Eng N; Maitland A
    J Med Case Rep; 2021 Dec; 15(1):620. PubMed ID: 34920756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1974-1984. PubMed ID: 35346887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
    Butterfield JH
    Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast Cell Activation Syndrome.
    Frieri M
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of Post-COVID syndromes: a new perspective.
    Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Welson NN
    Virol J; 2022 Oct; 19(1):158. PubMed ID: 36210445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mast Cell Activation Syndrome in COVID-19 and Female Reproductive Function: Theoretical Background vs. Accumulating Clinical Evidence.
    Szukiewicz D; Wojdasiewicz P; Watroba M; Szewczyk G
    J Immunol Res; 2022; 2022():9534163. PubMed ID: 35785029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mast cell activation syndrome: a review.
    Frieri M; Patel R; Celestin J
    Curr Allergy Asthma Rep; 2013 Feb; 13(1):27-32. PubMed ID: 23179866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
    Castells M; Butterfield J
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1097-1106. PubMed ID: 30961835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mast cell mediators in allergic inflammation and mastocytosis.
    Castells M
    Immunol Allergy Clin North Am; 2006 Aug; 26(3):465-85. PubMed ID: 16931289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of in vivo mast cell reactivity in patients with systemic mastocytosis.
    Gülen T; Möller Westerberg C; Lyberg K; Ekoff M; Kolmert J; Bood J; Öhd J; James A; Dahlén SE; Nilsson G; Dahlén B
    Clin Exp Allergy; 2017 Jul; 47(7):909-917. PubMed ID: 28258965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tryptase levels in patients with post-acute COVID-19 syndrome.
    Hadak A; Premec D; Perkovic M; Dolenec V; Bozan M; Nedeljkovic V; Kelava T; Markovic I
    Bratisl Lek Listy; 2024; 125(5):318-321. PubMed ID: 38624057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells.
    Veien M; Szlam F; Holden JT; Yamaguchi K; Denson DD; Levy JH
    Anesthesiology; 2000 Apr; 92(4):1074-81. PubMed ID: 10754628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
    Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME;
    J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
    Ravi A; Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mast cell activation is associated with post-acute COVID-19 syndrome.
    Wechsler JB; Butuci M; Wong A; Kamboj AP; Youngblood BA
    Allergy; 2022 Apr; 77(4):1288-1291. PubMed ID: 34820848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.